A Phase 2 interventional study of LTP001 and Placebo in Idiopathic Pulmonary Fibrosis, sponsored by Novartis Pharmaceuticals. Terminated at 15 sites in 7 countries. Open to participants aged 40 Years to 100 Years. Per ClinicalTrials.gov, last updated 2026-01-13.
Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 29 studies in Idiopathic Pulmonary Fibrosis with a site in Argentina — 5 open to participants now, 11 under way, 4 of them phase 3. Idiopathic Pulmonary Fibrosis · Argentina.
Among the 29 studies in Idiopathic Pulmonary Fibrosis with a site in Argentina, this one is the 29th largest by enrollment, is one of 6 that started in 2022, is one of 17 in phase 2, and was the 16th registered.
577 studies on the registry are indexed under Idiopathic Pulmonary Fibrosis; 124 are open to participants now.
Browse Idiopathic Pulmonary Fibrosis studies →5 of the 29 studies in Idiopathic Pulmonary Fibrosis with a site in Argentina are open now. Recruiting first, the newest first:
AstraZeneca · Sites in Argentina, United States, Australia and 20 more countries
Ages 40+
Contineum Therapeutics · Sites in Argentina, Australia, Belgium and 16 more countries
Ages 40+
Avalyn Pharma Inc. · Sites in Argentina, United States, Australia and 10 more countries
Ages 18+
United Therapeutics · Sites in Argentina, United States, Australia and 15 more countries
Ages 40+
Bristol-Myers Squibb · Sites in Argentina, United States, Australia and 24 more countries
A study can be open while its sites in Argentina have not opened yet or have stopped. Only those recruiting at a site in Argentina →
Of the 86 Idiopathic Pulmonary Fibrosis studies recruiting now, 56 (65%) set no upper age limit and 8 (9%) stop at 75 or younger; 3 take children under 18; 15 take healthy volunteers.
This study: 40 Years to 100 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
29 studies; the count open now beside each. This study's row is marked.
First in 2008; this study’s year is marked. 6 started in 2022.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 46 is below the median of 55 across 390 interventional studies indexed under Idiopathic Pulmonary Fibrosis.
Median enrollment 340 across the 29 interventional studies. Of the 18 that completed or were terminated, 16 (89%) have results posted.
This tab as a report to print or save as PDF → With an account.
29 of 29 have an industry lead sponsor. The 10 most frequent:
This study is registered under Novartis Pharmaceuticals, one of the names counted as Novartis. Under that name alone:
Novartis Pharmaceuticals is the lead sponsor of 2,719 studies on the registry; 222 are open to participants now.
Of its 585 completed or terminated interventional studies of FDA-regulated products, 439 (75%) have results posted.
Novartis has 4 studies filed under Idiopathic Pulmonary Fibrosis — fewer than ten, so there is no comparison to draw.
3 of the studies in Idiopathic Pulmonary Fibrosis with a site in Argentina that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06238622Phase 3Boehringer IngelheimA Follow-up Study to Test Long-term Treatment With Nerandomilast in People With Pulmonary Fibrosis Who Took Part in a Previous Study With Nerandomilast | 2027-04-28 |
| NCT06588686Vicore Pharma ABA Trial to Evaluate Efficacy and Safety of Buloxibutid in People With Idiopathic Pulmonary Fibrosis. | 2027-05 |
| NCT06967805Mediar TherapeuticsWISPer: Evaluation of MTX-463 in Participants With Idiopathic Pulmonary Fibrosis (IPF) | 2027-08 |
Add all 3 to your calendar (.ics) → With an account.
Among the 29 studies in Idiopathic Pulmonary Fibrosis with a site in Argentina, from their registry updates:
This tab as a report to print or save as PDF → With an account.
A participant- and investigator-blinded, randomized, placebo-controlled, multicenter, platform study to investigate efficacy, safety, and tolerability of various single treatments in participants with idiopathic pulmonary fibrosis
This was a randomized, placebo-controlled, participant- and investigator-blinded platform study in participants with idiopathic pulmonary fibrosis. Participants underwent a screening period of 42 days, a treatment period of 26 weeks and a post-treatment safety follow-up period of 30 days. This study was designed to safely allow rapid and efficient screening of potentially efficacious investigational products in participants with IPF. The study was terminated for strategic reasons and no additional cohorts were created.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Additional protocol-defined inclusion / exclusion criteria may apply.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
FEV1
From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
LTP001 orally once daily in the morning for approximately 26 weeks.
Drug: LTP001 · Drug: Standard of Care (SoC)
Placebo orally once daily in the morning for approximately 26 weeks.
Drug: Placebo · Drug: Standard of Care (SoC)
LTP001 administered once daily in the morning
Placebo to LTP001 administered once daily in the morning
nintedanib, pirfenidone, or neither
Change From Baseline to End of Treatment Epoch in Forced Vital Capacity (FVC) Expressed in Percent Predicted
Forced Vital Capacity (FVC) is the total amount of air exhaled during the Forced expiratory volume (FEV) test measured through spirometry testing. FEV measures how much air a person can exhale during a forced breath. It is expressed as percent predicted, defined as FVC of the participant divided by the average FVC in the population for any person of similar age, sex, and body composition multiplied by 100. A positive change from baseline is considered a favorable outcome.
Time frame: Baseline, up to approximately 26 weeks
Change From Baseline to End of Treatment Epoch in FVC
Forced Vital Capacity (FVC) is the total amount of air exhaled during the Forced expiratory volume (FEV) test measured through spirometry testing. FEV measures how much air a person can exhale during a forced breath. A positive change from baseline is considered a favorable outcome.
Time frame: Baseline, up to approximately 26 weeks
Progression-free Survival (PFS)
PFS is defined as the time from the date of randomization to the date of the any of the following events: Absolute reduction from baseline of ≥10% predicted in FVC, Nonelective hospitalization for respiratory events, Lung Transplant, Death. PFS was analyzed based on Kaplan-Meier estimates.
Time frame: Baseline, up to approximately 26 weeks
Number of Participants With Absolute Decline of ≥10% Predicted in FVC
Binary output of absolute decline of ≥ 10% predicted in FVC (Yes/No) at the end of treatment epoch.
Time frame: Baseline, up to approximately 26 weeks
Change From Baseline to the End of Treatment Epoch in Diffusion Capacity of Lung for Carbon Monoxide (DLCO)
Diffusing capacity of the lungs for carbon monoxide (DLCO) is a measurement to assess the ability of the lungs to transfer gas from inspired air to the bloodstream. Inhaled carbon monoxide (CO) is used for this test due to its high affinity for hemoglobin. During a ten-second breath-hold, DLCO measures uptake of CO per time per CO pressure.
Time frame: Baseline, up to approximately 26 weeks
Change From Baseline to the End of Treatment Epoch in 6-minute Walk Distance (6MWD)
The 6MWD test is self-paced, with standardized instructions and encouragement being given as participants walk as far as possible over 6 minutes through a flat corridor. The final distance is recorded in meters. A positive change from baseline in 6MWD is considered a favourable outcome.
Time frame: Baseline, up to approximately 26 weeks
Change From Baseline to the End of Treatment Epoch in Total Score From the K-BILD Questionnaire
The King's Brief Interstitial Lung Disease (K-BILD) is a 15-item HRQOL questionnaire that range from 0 to 100. Higher scores indicate better health-related quality of life, with 100 representing the best possible health status. A positive change from baseline in K-BILD questionnaire is considered a favourable outcome.
Time frame: Baseline, up to approximately 26 weeks
Change From Baseline to the End of Treatment Epoch in Scores From Leicester Cough Questionnaire
The Leicester Cough Questionnaire (LCQ) is a 19-item validated patient-report questionnaire that measures the impact of cough on quality of life. It takes about 5 minutes to complete and results in three domain scores (Social, Psychological, and Physical), and one Total score. Domain scores are averages of the questions that make up each domain. Minimum and maximum domain scores are 1 and 7, respectively. The domain scores are summed to determine the Total score, which can range from 3 to 21. A higher score means less impact on quality of life. A positive LCQ change score indicates an improvement.
Time frame: Baseline, up to approximately 26 weeks
Change From Baseline to the End of Treatment Epoch in Scores From the the R-Scale for IPF Questionnaire
The Raghu-Scale for Pulmonary Fibrosis (R-Scale for PF) is a questionnaire designed to assess the impact of lung disease on quality of life. The R-Scale-PF uses a numerical rating scale to assess the severity of five symptoms: cough, shortness of breath, fatigue, depressed mood, and overall sense of wellbeing, over the past two weeks. Each item is scored from 0 to 10, with lower scores indicating better health-related quality of life. The total R-Scale-PF score ranges from 0 to 50. A decrease from baseline in R-Scale for PF is considered a favourable outcome.
Time frame: Baseline, up to approximately 26 weeks
Change From Baseline to the End of Treatment Epoch in Total Score From the Living With IPF Questionnaire
Living with idiopathic pulmonary fibrosis (L-IPF) is a tool that assesses symptoms and impacts of IPF. The Symptoms Module consists of 20 questions to assess symptoms experienced from IPF over the last 24 hours. The Impacts Module consists of 20 questions on how IPF affects quality of life over the last 7 days. The total score ranging from 0 to 100, with higher scores indicating greater symptom severity. A positive change from baseline in L-IPF is considered a favourable outcome.
Time frame: Baseline, up to approximately 26 weeks
Participants took part at 15 investigative sites in 7 countries.
| Milestone | LTP001 6mg | Placebo |
|---|---|---|
| Started | 23 | 23 |
| Completed | 15 | 17 |
| Not completed | 8 | 6 |
| Withdrew: Adverse event | 1 | 0 |
| Withdrew: Physician decision | 0 | 1 |
| Withdrew: Study terminated by sponsor | 7 | 4 |
| Withdrew: Subject decision | 0 | 1 |
Forced Vital Capacity (FVC) is the total amount of air exhaled during the Forced expiratory volume (FEV) test measured through spirometry testing. FEV measures how much air a person can exhale during a forced breath. It is expressed as percent predicted, defined as FVC of the participant divided by the average FVC in the population for any person of similar age, sex, and body composition multiplied by 100. A positive change from baseline is considered a favorable outcome.
| Percentage of predicted FVC | LTP001 6mg | Placebo |
|---|---|---|
| Change From Baseline to End of Treatment Epoch in Forced Vital Capacity (FVC) Expressed in Percent Predicted | -3.1 ± 4.80 | -1.1 ± 5.31 |
Forced Vital Capacity (FVC) is the total amount of air exhaled during the Forced expiratory volume (FEV) test measured through spirometry testing. FEV measures how much air a person can exhale during a forced breath. A positive change from baseline is considered a favorable outcome.
| mL | LTP001 6mg | Placebo |
|---|---|---|
| Change From Baseline to End of Treatment Epoch in FVC | -120.0 ± 181.56 | -45.5 ± 176.25 |
PFS is defined as the time from the date of randomization to the date of the any of the following events: Absolute reduction from baseline of ≥10% predicted in FVC, Nonelective hospitalization for respiratory events, Lung Transplant, Death. PFS was analyzed based on Kaplan-Meier estimates.
| Days | LTP001 6mg | Placebo |
|---|---|---|
| Progression-free Survival (PFS) | 185.0 (180.0 to NA) | 185.0 (183.0 to NA) |
Binary output of absolute decline of ≥ 10% predicted in FVC (Yes/No) at the end of treatment epoch.
| Participants | LTP001 6mg | Placebo |
|---|---|---|
| Number of Participants With Absolute Decline of ≥10% Predicted in FVC | 6 | 5 |
Diffusing capacity of the lungs for carbon monoxide (DLCO) is a measurement to assess the ability of the lungs to transfer gas from inspired air to the bloodstream. Inhaled carbon monoxide (CO) is used for this test due to its high affinity for hemoglobin. During a ten-second breath-hold, DLCO measures uptake of CO per time per CO pressure.
| mL/min/mmHg | LTP001 6mg | Placebo |
|---|---|---|
| Change From Baseline to the End of Treatment Epoch in Diffusion Capacity of Lung for Carbon Monoxide (DLCO) | -0.167 ± 1.5568 | -0.334 ± 2.3838 |
The 6MWD test is self-paced, with standardized instructions and encouragement being given as participants walk as far as possible over 6 minutes through a flat corridor. The final distance is recorded in meters. A positive change from baseline in 6MWD is considered a favourable outcome.
| meters | LTP001 6mg | Placebo |
|---|---|---|
| Change From Baseline to the End of Treatment Epoch in 6-minute Walk Distance (6MWD) | 9.2 ± 63.06 | 4.7 ± 56.66 |
The King's Brief Interstitial Lung Disease (K-BILD) is a 15-item HRQOL questionnaire that range from 0 to 100. Higher scores indicate better health-related quality of life, with 100 representing the best possible health status. A positive change from baseline in K-BILD questionnaire is considered a favourable outcome.
| score on scale | LTP001 6mg | Placebo |
|---|---|---|
| Change From Baseline to the End of Treatment Epoch in Total Score From the K-BILD Questionnaire | 17.17 ± 174.009 | 7.94 ± 136.768 |
The Leicester Cough Questionnaire (LCQ) is a 19-item validated patient-report questionnaire that measures the impact of cough on quality of life. It takes about 5 minutes to complete and results in three domain scores (Social, Psychological, and Physical), and one Total score. Domain scores are averages of the questions that make up each domain. Minimum and maximum domain scores are 1 and 7, respectively. The domain scores are summed to determine the Total score, which can range from 3 to 21. A higher score means less impact on quality of life. A positive LCQ change score indicates an improvement.
| score on scale | LTP001 6mg | Placebo |
|---|---|---|
| Change From Baseline to the End of Treatment Epoch in Scores From Leicester Cough Questionnaire | -3.9 ± 14.23 | 2.7 ± 18.35 |
The Raghu-Scale for Pulmonary Fibrosis (R-Scale for PF) is a questionnaire designed to assess the impact of lung disease on quality of life. The R-Scale-PF uses a numerical rating scale to assess the severity of five symptoms: cough, shortness of breath, fatigue, depressed mood, and overall sense of wellbeing, over the past two weeks. Each item is scored from 0 to 10, with lower scores indicating better health-related quality of life. The total R-Scale-PF score ranges from 0 to 50. A decrease from baseline in R-Scale for PF is considered a favourable outcome.
| score on scale | LTP001 6mg | Placebo |
|---|---|---|
| Change From Baseline to the End of Treatment Epoch in Scores From the the R-Scale for IPF Questionnaire | 1.53 ± 5.784 | -0.93 ± 6.020 |
Living with idiopathic pulmonary fibrosis (L-IPF) is a tool that assesses symptoms and impacts of IPF. The Symptoms Module consists of 20 questions to assess symptoms experienced from IPF over the last 24 hours. The Impacts Module consists of 20 questions on how IPF affects quality of life over the last 7 days. The total score ranging from 0 to 100, with higher scores indicating greater symptom severity. A positive change from baseline in L-IPF is considered a favourable outcome.
| score on scale | LTP001 6mg | Placebo |
|---|---|---|
| Change From Baseline to the End of Treatment Epoch in Total Score From the Living With IPF Questionnaire | 7.15 ± 14.392 | -4.48 ± 11.067 |
Collected over Adverse events were reported from first dose of study treatment until end of study treatment plus follow up period, up to a maximum duration of approximately 30 weeks.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| LTP001 6 mg | 1/23 (4.3%) | 2/23 (8.7%) | 14/23 (60.9%) |
| Placebo | 0/23 (0%) | 1/23 (4.3%) | 7/23 (30.4%) |
| Total | 1/46 (2.2%) | 3/46 (6.5%) | 21/46 (45.7%) |
| Event | LTP001 6 mg | Placebo | Total |
|---|---|---|---|
| Herpes zosterInfections and infestations | 1/23 | 0/23 | 1/46 |
| InfectionInfections and infestations | 1/23 | 0/23 | 1/46 |
| Bladder disorderRenal and urinary disorders | 1/23 | 0/23 | 1/46 |
| Idiopathic pulmonary fibrosisRespiratory, thoracic and mediastinal disorders | 1/23 | 1/23 | 2/46 |
| Event | LTP001 6 mg | Placebo | Total |
|---|---|---|---|
| DiarrhoeaGastrointestinal disorders | 5/23 | 1/23 | 6/46 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 3/23 | 1/23 | 4/46 |
| BronchitisInfections and infestations | 2/23 | 0/23 | 2/46 |
| PneumoniaInfections and infestations | 0/23 | 2/23 | 2/46 |
| Urinary tract infectionInfections and infestations | 1/23 | 2/23 | 3/46 |
| Amylase increasedInvestigations | 2/23 | 0/23 | 2/46 |
| Lipase increasedInvestigations | 2/23 | 0/23 | 2/46 |
| HeadacheNervous system disorders | 1/23 | 2/23 | 3/46 |
| CoughRespiratory, thoracic and mediastinal disorders | 2/23 | 1/23 | 3/46 |
| HypertensionVascular disorders | 2/23 | 0/23 | 2/46 |
| Age, Continuous(Years) | LTP001 6mg | Placebo | Total |
|---|---|---|---|
| Mean | 70.3 ± 7.07 | 69.5 ± 5.34 | 69.9 ± 6.21 |
| Sex: Female, Male(Participants) | LTP001 6mg | Placebo | Total |
|---|---|---|---|
| Female | 2 | 11 | 13 |
| Male | 21 | 12 | 33 |
| Race/Ethnicity, Customized(Participants) | LTP001 6mg | Placebo | Total |
|---|---|---|---|
| White | 23 | 23 | 46 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations. This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com
Ran from Nov 2022 to primary completion in Aug 2024, 21 months.
Results were first posted in Sep 2025, 1 year after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in Dec 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: LTP001
Idiopathic Pulmonary Fibrosis →